Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

A study published in the New England Journal of Medicine in June 2026 examined long-term outcomes of CAR T-cell therapies in patients with B-cell lymphomas over a ten-year period. CAR T-cell therapies are specialized treatments in which a patient's immune cells are genetically modified to recognize and destroy cancer cells. The research focused on the safety and efficacy of this treatment over a long-term horizon. The study provides important data on how long patients remain disease-free and what adverse effects may occur over a longer time period. These findings are relevant for better understanding the potential of CAR T-cell therapies as a long-term therapeutic approach in hematologic malignancies.